Cabaletta Bio Total Debt vs. Current Valuation
| CABA Stock | USD 2.42 0.13 5.68% |
For Cabaletta Bio profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cabaletta Bio to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cabaletta Bio utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cabaletta Bio's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cabaletta Bio over time as well as its relative position and ranking within its peers.
Cabaletta |
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cabaletta Bio. If investors know Cabaletta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cabaletta Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cabaletta Bio is measured differently than its book value, which is the value of Cabaletta that is recorded on the company's balance sheet. Investors also form their own opinion of Cabaletta Bio's value that differs from its market value or its book value, called intrinsic value, which is Cabaletta Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cabaletta Bio's market value can be influenced by many factors that don't directly affect Cabaletta Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cabaletta Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cabaletta Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cabaletta Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cabaletta Bio Current Valuation vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Cabaletta Bio's current stock value. Our valuation model uses many indicators to compare Cabaletta Bio value to that of its competitors to determine the firm's financial worth. Cabaletta Bio is rated below average in total debt category among its peers. It is rated below average in current valuation category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cabaletta Bio's earnings, one of the primary drivers of an investment's value.Cabaletta Total Debt vs. Competition
Cabaletta Bio is rated below average in total debt category among its peers. Total debt of Health Care industry is currently estimated at about 584.22 Million. Cabaletta Bio maintains roughly 5.02 Million in total debt contributing less than 1% to equities under Health Care industry.
Cabaletta Current Valuation vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Cabaletta Bio |
| = | 5.02 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Cabaletta Bio |
| = | (76.39 M) |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Cabaletta Current Valuation vs Competition
Cabaletta Bio is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 21.98 Billion. Cabaletta Bio has negative current valuation of (76.39 Million) contributing less than 1% to the industry.
Cabaletta Bio Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Cabaletta Bio, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cabaletta Bio will eventually generate negative long term returns. The profitability progress is the general direction of Cabaletta Bio's change in net profit over the period of time. It can combine multiple indicators of Cabaletta Bio, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Cabaletta Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 57 people.
Cabaletta Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Cabaletta Bio. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cabaletta Bio position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cabaletta Bio's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Cabaletta Bio without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Latest Portfolios Now
Latest PortfoliosQuick portfolio dashboard that showcases your latest portfolios |
| All Next | Launch Module |
Use Investing Themes to Complement your Cabaletta Bio position
In addition to having Cabaletta Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aggressive Funds Thematic Idea Now
Aggressive Funds
Funds or Etfs that attempt to achieve high capital gains by investing in companies with high growth potential and above average risk. The Aggressive Funds theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. For information on how to trade Cabaletta Stock refer to our How to Trade Cabaletta Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
To fully project Cabaletta Bio's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Cabaletta Bio at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Cabaletta Bio's income statement, its balance sheet, and the statement of cash flows.